Valeant Pharmaceuticals Intl Inc. (TSX:VRX) Rockets Past 52-Week Highs: Time to Buy?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares have been rocketing of late. Here’s what investors should do today as the company returns on the growth track.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares have been on fire of late, surging ~16% over the last two days on increased optimism over upcoming drug launches. This was sparked by an upgrade from Barclays’ analyst Douglas Tsao, who believes the stock has finally hit an “inflection point.” With three promising drugs in Duobrii, Bryhali and Altreno slated to launch in 2018 and more to come next year, the odds of yielding a “blockbuster” drug look to be increasing.

In many previous pieces, I’ve been pounding the table pretty hard when it came to Valeant as the company moved away from damage control and into full-on growth mode. I even called Valeant one of my top rebound stock for 2018 back in January.

The progress that CEO Joe Papa has made during his short time at the company can only be described as remarkable. Through calculated non-core asset sales, Papa has earned the company enough wiggle room to focus on earnings growth initiatives, rather than revenue-stunting asset sales in order to bring the debt-load back down to reasonable levels.

Sure, there’s still over $25 billion in debt plaguing the balance sheet, but as Papa has noted many times in the past, he’s in no rush to bring the debt down to a level that would be deemed healthy by your average analyst over the near-term. While Papa could certainly continue his streak of offloading assets in order to chip away at debt further, he’s chosen to roll with the punches instead and deal with debt maturities as they come.

Irina Koffler, a senior analyst at Mizuho, also added fuel to Valeant’s rally by noting that the company’s portfolio of drugs is “Mylanlike” thanks to the consumer-oriented nature of its offerings. Approximately ~50% of Valeant’s revenues are derived from such stable products as contact lenses and various other over-the-counter offerings.

Bottom line

With many revenue-driving drugs poised to pop out of the pipeline over the near-term, it’s not a mystery as to why analysts and investors have been growing increasingly bullish on the stock. Insiders have also have eaten their own cooking over the past year, scooping up over $6 million worth of their own shares over the last 10 months.

Given Papa’s incredible track record, Valeant’s incoming return to revenue growth and the stock’s modest valuation, I’d encourage investors to scale into a position today before more analysts jump onto the bandwagon, which could send shares into the atmosphere.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Double exposure of a businessman and stairs - Business Success Concept
Investing

Better Buy: RBC Stock or the Entire TSX?

Royal Bank of Canada (TSX:RY) is a robust stock, but the index fund could be better long term.

Read more »

Family relationship with bond and care
Investing

Retirees: 2 Top TSX Dividend Stocks to Buy for TFSA Passive Income

Top TSX dividend stocks now trade at discounted prices for TFSA investors seeking passive income.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Metals and Mining Stocks

Beat the TSX With This Unstoppable Dividend Stock

This dividend stock continues to outpace the TSX and then some, providing you with a dividend that you'll want to…

Read more »

Energy Stocks

Here’s My Top Stock to Buy Now, and it’s Not Even a Question

Tourmaline is a quality energy stock trading on the TSX. Here's why I remain bullish on TOU stock right now.

Read more »

Dice engraved with the words buy and sell
Tech Stocks

Selling Losers Before 2023? Buy These 2 TSX Stocks With the Proceeds 

There is one month to 2023. Now is the time to sell your loss-making stocks, take the tax advantage, and…

Read more »

A meter measures energy use.
Dividend Stocks

TFSA Investors: 3 Safe Utility Stocks to Buy and Hold for Decades

Here are three top utilities to spend some fresh TFSA cash on in the new year.

Read more »

money cash dividends
Dividend Stocks

TFSA Investors: An Easy Way to Boost Your Payouts to $350 Per Month

Because of the tax-free nature of the TFSA, investors have several advantages, especially when buying high-quality dividend stocks.

Read more »

Piggy bank next to a financial report
Investing

How to Turn $10,000 Into $200,000 for Retirement

Buy top dividend stocks and use the distributions to acquire new shares.

Read more »